Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced ovarian cancer. A Southwest Oncology Group Study

D. D. Von Hoff, R. Kronmal, R. V. O'Toole, E. A. Surwit, J. J. Hutton, David S Alberts

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Fourteen evaluable patients with advanced ovarian cancer refractory to one prior chemotherapy regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicity was granulocytopenia with 50% of patients having granulocyte counts of <1,000/μl. Based on this study and one other previously published trial, fludarabine phosphate does not appear to be an active agent for patients with refractory ovarian cancer.

Original languageEnglish (US)
Pages (from-to)146-148
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume11
Issue number2
StatePublished - 1988
Externally publishedYes

Fingerprint

fludarabine phosphate
Ovarian Neoplasms
Agranulocytosis
Proxy
Granulocytes
Appointments and Schedules
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced ovarian cancer. A Southwest Oncology Group Study. / Von Hoff, D. D.; Kronmal, R.; O'Toole, R. V.; Surwit, E. A.; Hutton, J. J.; Alberts, David S.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 11, No. 2, 1988, p. 146-148.

Research output: Contribution to journalArticle

@article{be77521323684c539ff1f07824e15679,
title = "Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced ovarian cancer. A Southwest Oncology Group Study",
abstract = "Fourteen evaluable patients with advanced ovarian cancer refractory to one prior chemotherapy regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicity was granulocytopenia with 50{\%} of patients having granulocyte counts of <1,000/μl. Based on this study and one other previously published trial, fludarabine phosphate does not appear to be an active agent for patients with refractory ovarian cancer.",
author = "{Von Hoff}, {D. D.} and R. Kronmal and O'Toole, {R. V.} and Surwit, {E. A.} and Hutton, {J. J.} and Alberts, {David S}",
year = "1988",
language = "English (US)",
volume = "11",
pages = "146--148",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced ovarian cancer. A Southwest Oncology Group Study

AU - Von Hoff, D. D.

AU - Kronmal, R.

AU - O'Toole, R. V.

AU - Surwit, E. A.

AU - Hutton, J. J.

AU - Alberts, David S

PY - 1988

Y1 - 1988

N2 - Fourteen evaluable patients with advanced ovarian cancer refractory to one prior chemotherapy regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicity was granulocytopenia with 50% of patients having granulocyte counts of <1,000/μl. Based on this study and one other previously published trial, fludarabine phosphate does not appear to be an active agent for patients with refractory ovarian cancer.

AB - Fourteen evaluable patients with advanced ovarian cancer refractory to one prior chemotherapy regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicity was granulocytopenia with 50% of patients having granulocyte counts of <1,000/μl. Based on this study and one other previously published trial, fludarabine phosphate does not appear to be an active agent for patients with refractory ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0023919641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023919641&partnerID=8YFLogxK

M3 - Article

C2 - 2451882

AN - SCOPUS:0023919641

VL - 11

SP - 146

EP - 148

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -